Key Details
Annual ROE
-70.70%Beta
-Events Calendar
Next earnings date:
N/ARecent quarterly earnings:
May 10, 2024Recent annual earnings:
Mar 15, 2023Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
19 Sept '23 Wedbush
Neutral19 Sept '23 Piper Sandler
Neutral19 Sept '23 Jefferies
Buy19 Sept '23 HC Wainwright & Co.
Neutral15 Aug '23 HC Wainwright & Co.
Buy08 June '23 HC Wainwright & Co.
Buy18 May '23 HC Wainwright & Co.
Buy12 May '23 Wedbush
Outperform12 May '23 Stifel
Hold20 Apr '23 HC Wainwright & Co.
BuyScreeners with KNTE included
No data
Market Data
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Dividend
Kinnate Biopharma doesn't have historical dividend data
Profitability
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Efficiency
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Valuation
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Liquidity
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Cash Flow
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Institutional Ownership
Similar stocks
Kinnate Biopharma Inc. (KNTE) Upgraded to Buy: What Does It Mean for the Stock?
KNTE
Zacks Investment Research28 February 2024
Kinnate Biopharma Inc. (KNTE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Kinnate Biopharma (KNTE) Falls 40% in a Month: Here's Why
KNTE
Zacks Investment Research03 October 2023
Kinnate Biopharma (KNTE) plunges 40% in a month for the decision to streamline its pipeline to one clinical candidate as part of its reprioritization efforts and slash workforce by 70%.
4 Penny Stocks To Buy According To Insiders This Quarter
KNTE
PennyStocks03 May 2023
Insiders think these are penny stocks to buy based on recent filings but are they worth the risk? The post 4 Penny Stocks To Buy According To Insiders This Quarter appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
FAQ
- What is the primary business of Kinnate Biopharma?
- What is the ticker symbol for Kinnate Biopharma?
- Does Kinnate Biopharma pay dividends?
- What sector is Kinnate Biopharma in?
- What industry is Kinnate Biopharma in?
- What country is Kinnate Biopharma based in?
- When did Kinnate Biopharma go public?
- Is Kinnate Biopharma in the S&P 500?
- Is Kinnate Biopharma in the NASDAQ 100?
- Is Kinnate Biopharma in the Dow Jones?
- When was Kinnate Biopharma's last earnings report?
- When does Kinnate Biopharma report earnings?
- Should I buy Kinnate Biopharma stock now?
What is the primary business of Kinnate Biopharma?
Kinnate Biopharma Inc., a clinical-stage oncology company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.
What is the ticker symbol for Kinnate Biopharma?
The ticker symbol for Kinnate Biopharma is NASDAQ:KNTE
Does Kinnate Biopharma pay dividends?
No, Kinnate Biopharma does not pay dividends
What sector is Kinnate Biopharma in?
Kinnate Biopharma is in the Healthcare sector
What industry is Kinnate Biopharma in?
Kinnate Biopharma is in the Biotechnology industry
What country is Kinnate Biopharma based in?
Kinnate Biopharma is headquartered in United States
When did Kinnate Biopharma go public?
Kinnate Biopharma's initial public offering (IPO) was on 03 December 2020
Is Kinnate Biopharma in the S&P 500?
No, Kinnate Biopharma is not included in the S&P 500 index
Is Kinnate Biopharma in the NASDAQ 100?
No, Kinnate Biopharma is not included in the NASDAQ 100 index
Is Kinnate Biopharma in the Dow Jones?
No, Kinnate Biopharma is not included in the Dow Jones index
When was Kinnate Biopharma's last earnings report?
Kinnate Biopharma's most recent earnings report was on 10 May 2024
When does Kinnate Biopharma report earnings?
The date for Kinnate Biopharma's next earnings report has not been announced yet
Should I buy Kinnate Biopharma stock now?
As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions